Pacira BioSciences, Inc. (PCRX) |
| 25.54 0.06 (0.24%) 07-13 16:00 |
| Open: | 25.395 |
| High: | 25.89 |
| Low: | 25.255 |
| Volume: | 437,576 |
| Market Cap: | 1,005(M) |
| PE Ratio: | 9.79 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 31.14 |
| Resistance 1: | 26.66 |
| Pivot price: | 24.94 |
| Support 1: | 23.78 |
| Support 2: | 22.00 |
| 52w High: | 27.64 |
| 52w Low: | 18.8 |
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
| EPS | 0.130 |
| Book Value | 16.630 |
| PEG Ratio | 11.21 |
| Gross Profit | 14.816 |
| Profit Margin (%) | 0.70 |
| Operating Margin (%) | 2.61 |
| Return on Assets (ttm) | 1.4 |
| Return on Equity (ttm) | 0.7 |
Wed, 08 Jul 2026
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Wed, 08 Jul 2026
Pacira uses stock awards to recruit 10 new employees - Stock Titan
Wed, 08 Jul 2026
Pacira BioSciences (PCRX) Wins Broader EXPAREL Reimbursement, Is The Stock Still Undervalued? - Sahm
Wed, 01 Jul 2026
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - TradingView
Wed, 01 Jul 2026
Pacira BioSciences Divests CryoTech to Zimmer Biomet - The Globe and Mail
Tue, 30 Jun 2026
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome - GuruFocus
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |